{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:23:57Z","timestamp":1785900237296,"version":"3.56.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.remnie.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T08:53:30Z","timestamp":1651049610000},"page":"202-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical application of [18F]FDG PET\/CT in follicular lymphoma"],"prefix":"10.1016","volume":"41","author":[{"given":"A.","family":"D\u00edaz-Silv\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"Ot\u00f3n-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Caresia-Ar\u00f3ztegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"del Puig C\u00f3zar-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Orcajo-Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Arcocha-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"Delgado-Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cabello-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2022.03.002_bib0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology."},{"key":"10.1016\/j.remnie.2022.03.002_bib0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/RLU.0000000000001718","article-title":"Multicenter comparison of contrast-enhanced FDG PET\/CT and 64-slice Multi\u2013Detector-row CT for initial staging and response evaluation at the end of treatment in patients with lymphoma","volume":"42","author":"G\u00f3mez Le\u00f3n","year":"2017","journal-title":"Clin Nucl Med."},{"key":"10.1016\/j.remnie.2022.03.002_bib0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.remnie.2022.03.002_bib0020","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00259-012-2079-y","article-title":"FDG PET\/CT predictive role in follicular lymphoma","volume":"39","author":"Lopci","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0025","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.13271","article-title":"Diagnosis and management of follicular lymphoma: a comprehensive review","volume":"103","author":"Dada","year":"2019","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0035","author":"Alonso"},{"key":"10.1016\/j.remnie.2022.03.002_bib0040","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0045","first-page":"298","article-title":"Basal 18F-FDG PET\/CT in follicular lymphoma: a comparison of metabolic and clinical variables in the prognostic assessment","volume":"35","author":"Jim\u00e9nez Londo\u00f1o","year":"2016","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0050","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1002\/cncr.30672","article-title":"[18 F]-FDG PET\/CT in the staging and management of indolent lymphoma: a prospective multicenter PET registry study","volume":"123","author":"Metser","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.remnie.2022.03.002_bib0055","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN clinical practice guidelines in oncology. B-cell lymphomas. Version 5.2021","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Cancer Netw."},{"key":"10.1016\/j.remnie.2022.03.002_bib0060","article-title":"Is it time for PET-guided therapy in follicular lymphoma","author":"Trotman","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2022.03.002_bib0065","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2012.45.4082","article-title":"Imaging follicular lymphoma using positron emission tomography with [18F]fluorodeoxyglucose: to what purpose?","volume":"30","author":"Barrington","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0070","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1158\/1078-0432.CCR-13-1511","article-title":"End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis","volume":"19","author":"Pyo","year":"2013","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2022.03.002_bib0075","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.remnie.2022.03.002_bib0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0085","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2022.03.002_bib0090","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the groupe d\u2019etudes des lymphomes de l\u2019adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0095","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann Hematol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","article-title":"Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma","volume":"71","author":"Wirth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.remnie.2022.03.002_bib0110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00259-008-0958-z","article-title":"Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study","volume":"36","author":"Scott","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0115","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0120","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0125","doi-asserted-by":"crossref","DOI":"10.1097\/RCT.0000000000000485","article-title":"Systematic review on the additional value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in staging follicular lymphoma","volume":"41","author":"Adams","year":"2017","journal-title":"J Comput Assist Tomogr."},{"key":"10.1016\/j.remnie.2022.03.002_bib0130","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the fondazione italiana linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/0284186X.2015.1041652","article-title":"Lymphoma grading with FDG-PET\/CT readdressed: direct and timely histopathological correlation study","volume":"55","author":"Adams","year":"2016","journal-title":"Acta Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0140","first-page":"312","article-title":"18F-FDG PET\/TC en el manejo cl\u00ednico de los linfomas","volume":"36","author":"Tamayo","year":"2017","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","article-title":"Positron-emission tomography\u2013based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","volume":"126","author":"Batlevi","year":"2020","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.remnie.2022.03.002_bib0150","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-hodgkin\u2019s lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0155","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00259-013-2686-2","article-title":"Current role of FDG PET\/CT in lymphoma","volume":"41","author":"Kostakoglu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10428194.2013.802784","article-title":"Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3-5 October 2012","volume":"55","author":"Meignan","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.remnie.2022.03.002_bib0165","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.2967\/jnumed.108.057190","article-title":"PET\/CT for therapy response assessment in lymphoma","volume":"50","author":"Hutchings","year":"2009","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2022.03.002_bib0170","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0175","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s11864-014-0278-4","article-title":"Role of PET in lymphoma","volume":"15","author":"Gallamini","year":"2014","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0185","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2017.029","article-title":"FDG-PET scan: a new paradigm for follicular lymphoma management","volume":"9","author":"Gallamini","year":"2017","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"10.1016\/j.remnie.2022.03.002_bib0190","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.semnuclmed.2017.09.004","article-title":"PET\/CT for lymphoma post-therapy response assessment in other lymphomas, response assessment for autologous stem cell transplant, and lymphoma follow-up","volume":"48","author":"Karls","year":"2018","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remnie.2022.03.002_bib0200","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2352-3026(14)70015-8","article-title":"PET-CT restaging: a surrogate for follicular lymphoma?","volume":"1","author":"Cheson","year":"2014","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0205","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","article-title":"Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma","volume":"48","author":"Bishu","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.remnie.2022.03.002_bib0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","article-title":"Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma","volume":"7","author":"Zinzani","year":"2007","journal-title":"Clin Lymphoma Myeloma."},{"key":"10.1016\/j.remnie.2022.03.002_bib0215","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0220","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00259-013-2441-8","article-title":"PET\/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study","volume":"41","author":"Tychyj-Pinel","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0225","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the fondazione italiana linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0230","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12149-014-0874-1","article-title":"The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma","volume":"28","author":"Lu","year":"2014","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remnie.2022.03.002_bib0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0240","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/10428194.2016.1213824","article-title":"[18F] positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice","volume":"58","author":"Wong-Sefidan","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.remnie.2022.03.002_bib0245","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/10428194.2016.1196815","article-title":"FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study","volume":"58","author":"Kostakoglu","year":"2017","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.remnie.2022.03.002_bib0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-015-2553-2","article-title":"Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0255","series-title":"NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 2.2018","author":"Zelenetz","year":"2018"},{"key":"10.1016\/j.remnie.2022.03.002_bib0260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13139-019-00602-0","article-title":"Predictive value of interim and end-of-therapy 18F-FDG PET\/CT in patients with follicular lymphoma","volume":"53","author":"Boo","year":"2019","journal-title":"Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0265","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-014-2973-6","article-title":"FDG PET\/CT imaging as a biomarker in lymphoma","volume":"42","author":"Meignan","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2022.03.002_bib0270","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.2147\/CMAR.S216445","article-title":"Prognostic values of baseline, interim and end-of therapy 18F-FDG PET\/CT in patients with follicular lymphoma","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res."},{"key":"10.1016\/j.remnie.2022.03.002_bib0275","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2022.03.002_bib0280","first-page":"340","article-title":"Evaluaci\u00f3n del valor pron\u00f3stico de los diferentes m\u00e9todos de c\u00e1lculo del volumen metab\u00f3lico tumoral con 18F-FDG PET\/TC, en pacientes con linfoma B difuso de c\u00e9lulas grandes","volume":"39","author":"Guzm\u00e1n Ortiz","year":"2020","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0285","first-page":"304","article-title":"Optimizaci\u00f3n de los criterios metab\u00f3licos en la valoraci\u00f3n pron\u00f3stica de los pacientes con linfoma. Estudio multic\u00e9ntrico","volume":"36","author":"del Puig C\u00f3zar-Santiago","year":"2017","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0290","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.remnie.2022.03.002_bib0295","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0300","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2016.70.6150","article-title":"On the cutoff of baseline total metabolic tumor volume in high-tumor-burden follicular lymphoma","volume":"35","author":"Laffon","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0305","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2016.70.4890","article-title":"Overestimated value of baseline total metabolic tumor volume at 18F-labeled fluorodeoxyglucose positron emission tomography in follicular lymphoma","volume":"35","author":"Adams","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remnie.2022.03.002_bib0310","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.remnie.2022.03.002_bib0315","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808922000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808922000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:44:05Z","timestamp":1762418645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808922000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2253808922000180"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2022.03.002","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical application of [18F]FDG PET\/CT in follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2022.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}